News | December 17, 2023
Dr. Reddy's becomes first Indian pharma company to debut on the DJSI
Dr. Reddy's has been awarded 'Gold Medal' status by EcoVadis
Dr. Reddy's has been awarded 'Gold Medal' status by EcoVadis
This development is a strategic part of the company's commitment to bolstering its position in the advanced pharmaceutical intermediates segment
Announces changes to commercial organization to prepare for multiple product launches in 2024 and 2025
The company makes its maiden entry into Azerbaijan’s pharmaceutical market
Mothers Against Vaping also highlights a recent study of young people at risk of experiencing significant respiratory symptoms after just 30 days of electronic cigarette and other new age gateway products use
Anticipates approx. US$8 billion in revenues for Comirnaty and Paxlovid
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
Demonstrate significant bleed reduction in hemophilia A and B
Subscribe To Our Newsletter & Stay Updated
